A Phase 1b-2 Study of KRT-232, a First-in-Class, Oral, Small Molecule Inhibitor of Murine Double Minute 2 (MDM2), in Combination with Acalabrutinib for the Treatment of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Anne Uyei,Catherine Thieblemont,Wojciech Jurczak,Peter Hillmen,Hope Qamoos,John C Byrd,Wayne M Rothbaum

doi:10.1182/blood-2020-134901

A Phase 1b-2 Study of KRT-232, a First-in-Class, Oral, Small Molecule Inhibitor of Murine Double Minute 2 (MDM2), in Combination with Acalabrutinib for the Treatment of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Anne Uyei, Catherine Thieblemont + Show 5 more

Open Access

https://doi.org/10.1182/blood-2020-134901

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2020
Citations: 2

Affiliation: The Maria Sklodowska-Curie National Research Institute of Oncology, St James's University Hospital, James Cancer Hospital

#For-profit Health Care Company #Equity Holder In Private Company + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

A Phase 1b-2 Study of KRT-232, a First-in-Class, Oral, Small Molecule Inhibitor of Murine Double Minute 2 (MDM2), in Combination with Acalabrutinib for the Treatment of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Full Text